Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study, Lancet Infect Dis, vol.18, pp.1191-1210, 2016. ,
Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine, Infect Dis Clin North Am, vol.29, pp.679-697, 2015. ,
Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects, Vaccine, vol.32, pp.133-145, 2013. ,
Serotype replacement in disease after pneumococcal vaccination, Lancet, vol.378, issue.10, pp.62225-62233, 2011. ,
Serotype-independent pneumococcal vaccines, Cell Mol Life Sci, vol.70, p.23269437, 2013. ,
The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro, Clin Vaccine Immunol, vol.19, pp.1574-1582, 2012. ,
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin, Infect Immun, vol.72, pp.5031-5040, 2004. ,
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice, PLoS One, vol.5, 2010. ,
Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae, PLoS One, vol.12, 2017. ,
Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae, Clin Vaccine Immunol, vol.21, p.24807055, 2014. ,
Whole-Genome Sequence of a Bordetella pertussis Brazilian Vaccine Strain, Genome Announc, vol.3, 2015. ,
Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e, PLoS One, vol.8, 2013. ,
Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection, Clin Vaccine Immunol, vol.17, pp.439-446, 2010. ,
A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide, Braz J Med Biol Res, vol.37, pp.1103-1109, 2004. ,
Production and purification of an untagged recombinant pneumococcal surface protein A (PspA4Pro) with high-purity and low endotoxin content, Appl Microbiol Biotechnol, vol.101, p.27889801, 2017. ,
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA, J Infect Dis, vol.182, pp.1694-1701, 2000. ,
Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production, Clin Vaccine Immunol, vol.15, pp.499-505, 2008. ,
Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A), Microb Pathog, vol.48, pp.205-213, 2010. ,
Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine, Infect Immun, vol.78, pp.3258-3271, 2010. ,
Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge, Microbes Infect, vol.10, pp.481-488, 2008. ,
Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection, J Infect Dis, vol.195, pp.185-193, 2007. ,
Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis, Proc Natl Acad Sci U S A, vol.93, pp.7944-7949, 1996. ,
Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis, Nat Biotechnol, vol.16, pp.454-457, 1998. ,
Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis, Infect Immun, vol.69, pp.5440-5446, 2001. ,
Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e, Vaccine, vol.29, pp.5502-5511, 2011. ,
Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes, Scand J Immunol, vol.58, pp.503-510, 2003. ,
Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role, Infect Immun, vol.70, pp.4142-4147, 2002. ,